Journal of visualized experiments : JoVE
August 1, 2025
Kwang-Mook Jung, Alex Mabou Tagne, Heidi C Avalos et al.
Δ9-tetrahydrocannabinol (THC) is responsible for the intoxicating (psychotropic) effects of cannabis and cannabis-derived products currently available in the legal and illegal markets. The psychotropic effects of THC are produced via activation of CB1 cannabinoid receptors in the brain, which are normally engaged by endogenous cannabinoid (endocannabinoid) substances. Outside the brain, THC...
Cannabis and Cannabinoid Research
December 1, 2024
Alexa Torrens, Alex Mabou Tagne, Adren Tran et al.
Introduction: Animal studies suggest that adolescent exposure to Δ9-tetrahydrocannabinol (Δ9-THC), the intoxicating constituent of cannabis, causes lasting functional alterations in brain and other organs. Those studies often neglect the impact that age- and sex-dependent differences in the distribution and metabolism of the drug might exert on its pharmacological effects. Here, we provide a...
Biomolecules
September 10, 2024
Valeria Lallai, TuKiet T Lam, Rolando Garcia-Milian et al.
Given the increasing use of cannabis in the US, there is an urgent need to better understand the drug's effects on central signaling mechanisms. Extracellular vesicles (EVs) have been identified as intercellular signaling mediators that contain a variety of cargo, including proteins. Here, we examined whether the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), alters EV...
The Journal of pharmacology and experimental therapeutics
April 2007
Marcello Solinas, Gianluigi Tanda, Zuzana Justinova et al.
Anandamide is an endogenous ligand for brain cannabinoid CB(1) receptors, but its behavioral effects are difficult to measure due to rapid inactivation. Here we used a drug-discrimination procedure to test the hypothesis that anandamide, given i.v. or i.p., would produce discriminative effects like those of delta-9-tetrahydrocannabinol (THC) in rats when its metabolic inactivation was...
Proceedings of the National Academy of Sciences
December 13, 2005
Gabriella Gobbi, Francis Rodriguez Bambico, Regina A. Mangieri et al.
675 citations
Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application. The active constituent of cannabis, delta9-tetrahydrocannabinol, acts by binding to brain CB1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of...